Our latest articles
Pfizer's Covid cash keeps the M&A scene alive, but few others developers dug deep in a quiet third quarter.
Talzenna scores in first-line prostate cancer irrespective of HRR status, but for now we only have Pfizer’s word for it.
Few developers are feeling bold enough to brave the markets, though the bigger deals are finding some support.
A November adcom could decide whether Zejula will lose yet more ground to Lynparza.
Relmada, Albireo and Mirum prepare for important clinical results, as Intercept is set back again.
Amicus and Astrazeneca have notable approaching Pdufa decisions, while a panel for GSK’s daprodustat could change the course of a controversial drug class.
A clinical hit could allow the group’s liquid biopsy to expand from breast cancer to ovarian.
Eisai is rewarded for doubling down on lecanemab with an apparent win that endorses 20 years of research.
Important data reveals are expected from Madrigal, Arrowhead and Ascendis, with details from Biogen and Eisai due at a conference.
Data are early, but the small group already claims that it could have the best-in-class exon skipper for Duchenne.